Zhongming Zhao

Prof. Zhongming Zhao

The University of Texas Health Science Center at Houston, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMaximilian Strunz
Maximilian Strunz
LSLukas M. Simon
Lukas M. Simon
MAMeshal Ansari
Meshal Ansari
JKJaymin J. Kathiriya
Jaymin J. Kathiriya
IAIlias Angelidis
Ilias Angelidis
HSHerbert B. Schiller
Herbert B. Schiller
The cell type specific sequences of transcriptional programs during lung regeneration have remained elusive. Using time-series single cell RNA-seq of the bleomycin lung injury model, we resolved transcriptional dynamics for 28 cell types. Trajectory modeling together with lineage tracing revealed that airway and alveolar stem cells converge on a unique Krt8 + transitional stem cell state during alveolar regeneration. These cells have squamous morphology, feature p53 and NFkB activation and display transcriptional features of cellular senescence. The Krt8+ state appears in several independent models of lung injury and persists in human lung fibrosis, creating a distinct cell–cell communication network with mesenchyme and macrophages during repair. We generated a model of gene regulatory programs leading to Krt8+ transitional cells and their terminal differentiation to alveolar type-1 cells. We propose that in lung fibrosis, perturbed molecular checkpoints on the way to terminal differentiation can cause aberrant persistence of regenerative intermediate stem cell states.

13 September 2013 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
Min ZhaoMin Zhao
Min Zhao
Qingguo WangQingguo Wang
Qingguo Wang
QWQuan Wang
Quan Wang
PJPeilin Jia
Peilin Jia
ZZZhongming Zhao
Zhongming Zhao
Copy number variation (CNV) is a prevalent form of critical genetic variation that leads to an abnormal number of copies of large genomic regions in a cell. Microarray-based comparative genome hybridization (arrayCGH) or genotyping arrays have been standard technologies to detect large regions subject to copy number changes in genomes until most recently high-resolution sequence data can be analyzed by next-generation sequencing (NGS). During the last several years, NGS-based analysis has been widely applied to identify CNVs in both healthy and diseased individuals. Correspondingly, the strong demand for NGS-based CNV analyses has fuelled development of numerous computational methods and tools for CNV detection. In this article, we review the recent advances in computational methods pertaining to CNV detection using whole genome and whole exome sequencing data. Additionally, we discuss their strengths and weaknesses and suggest directions for future development.

20 November 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
Min ZhaoMin Zhao
Min Zhao
PKPora Kim
Pora Kim
Ramkrishna MitraRamkrishna Mitra
Ramkrishna Mitra
JZJunfei Zhao
Junfei Zhao
ZZZhongming Zhao
Zhongming Zhao
Tumor suppressor genes (TSGs) are a major type of gatekeeper genes in the cell growth. A knowledgebase with the systematic collection and curation of TSGs in multiple cancer types is critically important for further studying their biological functions as well as for developing therapeutic strategies. Since its development in 2012, the Tumor Suppressor Gene database (TSGene), has become a popular resource in the cancer research community. Here, we reported the TSGene version 2.0, which has substantial updates of contents (e.g. up-to-date literature and pan-cancer genomic data collection and curation), data types (noncoding RNAs and protein-coding genes) and content accessibility. Specifically, the current TSGene 2.0 contains 1217 human TSGs (1018 protein-coding and 199 non-coding genes) curated from over 9000 articles. Additionally, TSGene 2.0 provides thousands of expression and mutation patterns derived from pan-cancer data of The Cancer Genome Atlas. A new web interface is available at http://bioinfo.mc.vanderbilt.edu/TSGene/. Systematic analyses of 199 non-coding TSGs provide numerous cancer-specific non-coding mutational events for further screening and clinical use. Intriguingly, we identified 49 protein-coding TSGs that were consistently down-regulated in 11 cancer types. In summary, TSGene 2.0, which is the only available database for TSGs, provides the most updated TSGs and their features in pan-cancer.

18 March 2014 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
FCFeixiong Cheng
Feixiong Cheng
ZZZhongming Zhao
Zhongming Zhao
Objective Drug–drug interactions (DDIs) are an important consideration in both drug development and clinical application, especially for co-administer

12 October 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
Min ZhaoMin Zhao
Min Zhao
JSJingchun Sun
Jingchun Sun
ZZZhongming Zhao
Zhongming Zhao
Tumor suppressor genes (TSGs) are guardian genes that play important roles in controlling cell proliferation processes such as cell-cycle checkpoints and inducing apoptosis. Identification of these genes and understanding their functions are critical for further investigation of tumorigenesis. So far, many studies have identified numerous TSGs and illustrated their functions in various types of tumors or normal samples. Furthermore, accumulating evidence has shown that non-coding RNAs can act as TSGs to prevent the tumorigenesis processes. Therefore, there is a growing demand to integrate TSGs with large-scale experimental evidence (e.g. gene expression and epigenetic signatures) to provide a comprehensive resource for further investigation of TSGs and their molecular mechanisms in cancer. To achieve this goal, we first developed a comprehensive literature-based database called TSGene (tumor suppressor gene database), freely available at http://bioinfo.mc.vanderbilt.edu/TSGene/. In the current release, TSGene contains 716 human (637 protein-coding and 79 non-coding genes), 628 mouse and 567 rat TSGs curated from UniProtKB, the Tumor Associated Gene database and 5795 PubMed abstracts. Additionally, the TSGene provides detailed annotations for each TSG, such as cancer mutations, gene expressions, methylation sites, TF regulations and protein–protein interactions.

6 November 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CDClemens Duerrschmid
Clemens Duerrschmid
Yanlin HeYanlin He
Yanlin He
CWChunmei Wang
Chunmei Wang
CLChia Li
Chia Li
JBJuan C Bournat
Juan C Bournat
ACAtul R Chopra
Atul R Chopra
Asprosin, a recently identified secreted hormone from adipose tissue, acts centrally to promote food intake. Asprosin is a recently discovered fasting-induced hormone that promotes hepatic glucose production. Here we demonstrate that asprosin in the circulation crosses the blood–brain barrier and directly activates orexigenic AgRP+ neurons via a cAMP-dependent pathway. This signaling results in inhibition of downstream anorexigenic proopiomelanocortin (POMC)-positive neurons in a GABA-dependent manner, which then leads to appetite stimulation and a drive to accumulate adiposity and body weight. In humans, a genetic deficiency in asprosin causes a syndrome characterized by low appetite and extreme leanness; this is phenocopied by mice carrying similar mutations and can be fully rescued by asprosin. Furthermore, we found that obese humans and mice had pathologically elevated concentrations of circulating asprosin, and neutralization of asprosin in the blood with a monoclonal antibody reduced appetite and body weight in obese mice, in addition to improving their glycemic profile. Thus, in addition to performing a glucogenic function, asprosin is a centrally acting orexigenic hormone that is a potential therapeutic target in the treatment of both obesity and diabetes.